News

A young woman developed cold agglutinin disease (CAD) secondary to pneumonia, but responded well to red blood cell transfusions and treatment with the antibiotic doxycycline, according to a U.S. report. When CAD occurs secondary to an infection, “supportive therapy and treatment of the underlying infection is sufficient,” researchers…

A rituximab-based therapy regimen successfully treated a 16-year-old girl with primary cold agglutinin disease (CAD), according to researchers in the U.S. who say the case represents “the youngest patient reported with this diagnosis.” The case study, “An unusual case of primary cold agglutinin-associated lymphoproliferative disease…

Long-term treatment with Enjaymo (sutimlimab-jome) in people with cold agglutinin disease (CAD) results in rapid and sustained reductions in red blood cell destruction and anemia, as well as clinically-meaningful reductions in fatigue. That’s according to 2.5 years of data from the Phase 3 CARDINAL clinical trial, which tested…

A man with cold agglutinin disease (CAD) was found to have another autoimmune condition called pernicious anemia and vitamin B12 deficiency, according to researchers in the U.S. who called the case a rare instance of “three ongoing medical conditions simultaneously.” The case study, “A Case Report of Cold…

An experimental treatment called HMBD-011, designed to target self-reactive antibodies and the immune B-cells that produce them, showed efficacy in a cellular model of cold agglutinin disease (CAD), according to new preclinical findings presented at a scientific conference. “HMBD-011 is a potentially first-in-class … antibody developed for treatment for…

Researchers have developed a new patient-reported outcome questionnaire to assess symptoms and the impacts to daily life associated with cold agglutinin disease (CAD). Called the CAD-Symptoms and Impact Questionnaire (CAD-SIQ), it was developed by analyzing responses from patient interviews. Reactions to cold environments and fatigue were the most commonly…

Dianthus Therapeutics plans to launch a proof-of-concept clinical trial of its therapy candidate DNTH103 in 2024 to test the efficacy of the complement inhibitor in people with cold agglutinin disease (CAD). Data from the trial would be expected in the second half of next year. Funding for the…

The induced reduction in body temperature during an emergency surgery to replace a damaged heart component revealed the presence of mild cold agglutinin disease (CAD) in a woman in India, a study reports. The case study, “Cardiopulmonary Bypass Surgery-Cold Alert!,” was published in Annals of Cardiac Anaesthesia.

Two infections complicated the case of a woman who had cold agglutinin disease (CAD) secondary to a rare autoimmune disorder called mixed connective tissue disease (MCTD). The woman was treated for a tuberculosis (TB) lung infection, after which immunosuppressant therapies for CAD and MCTD triggered a second viral infection,…

Among people who meet the criteria for a blood condition called IgM monoclonal gammopathy of undetermined significance (IgM-MGUS), those with cold agglutinin disease (CAD) show distinct clinical and laboratory features from those without, a study shows. IgM-MGUS is marked by the excessive production of immunoglobulin M (IgM), a type…